{"name": "Naurex",
 "permalink": "naurex",
 "crunchbase_url": "http://www.crunchbase.com/company/naurex",
 "homepage_url": "http://www.naurex.com",
 "blog_url": "",
 "blog_feed_url": "",
 "twitter_username": "",
 "category_code": "biotech",
 "number_of_employees": null,
 "founded_year": null,
 "founded_month": null,
 "founded_day": null,
 "deadpooled_year": null,
 "deadpooled_month": null,
 "deadpooled_day": null,
 "deadpooled_url": null,
 "tag_list": "",
 "alias_list": "",
 "email_address": "corporate@naurex.com",
 "phone_number": "847-871-0377",
 "description": "",
 "created_at": "Thu May 12 03:24:48 UTC 2011",
 "updated_at": "Tue Dec 18 03:20:02 UTC 2012",
 "overview": "\u003Cp\u003ENaurex Inc. is a clinical-stage company developing novel therapies for depression and other CNS disorders based on a new mechanism of action for modulating the N-methyl-D-aspartic acid receptor (NMDAR). Using these discoveries, Naurex researchers have generated novel chemical drug classes known as glycine-site functional partial agonists (GFPAs), which modulate the receptor in a different way than existing NMDAR agents. The company\u00e2\u20ac\u2122s drug development programs based on its GFPA NMDAR modulators include the first-generation molecule, GLYX-13, the second-generation NRX-1050 small molecule series and additional compounds from Naurex\u00e2\u20ac\u2122s platform of novel NMDAR modulators.\u003C/p\u003E",
 "image":
  {"available_sizes":
    [[[150,
       49],
      "assets/images/resized/0013/4243/134243v1-max-150x150.jpg"],
     [[240,
       79],
      "assets/images/resized/0013/4243/134243v1-max-250x250.jpg"],
     [[240,
       79],
      "assets/images/resized/0013/4243/134243v1-max-450x450.jpg"]],
   "attribution": null},
 "products":
  [],
 "relationships":
  [],
 "competitions":
  [],
 "providerships":
  [],
 "total_money_raised": "$56M",
 "funding_rounds":
  [{"round_code": "a",
    "source_url": "http://www.fiercebiotech.com/story/naurex-raises-18m-ph2-depression-program/2011-05-11?utm_medium=rss\u0026utm_source=rss",
    "source_description": "Naurex raises $18M for Ph2 depression program",
    "raised_amount": 18000000.0,
    "raised_currency_code": "USD",
    "funded_year": 2011,
    "funded_month": 5,
    "funded_day": 11,
    "investments":
     [{"company": null,
       "financial_org":
        {"name": "Adams Street Partners",
         "permalink": "adams-street-partners",
         "image":
          {"available_sizes":
            [[[150,
               48],
              "assets/images/resized/0001/4352/14352v1-max-150x150.png"],
             [[185,
               60],
              "assets/images/resized/0001/4352/14352v1-max-250x250.png"],
             [[185,
               60],
              "assets/images/resized/0001/4352/14352v1-max-450x450.png"]],
           "attribution": null}},
       "person": null},
      {"company": null,
       "financial_org":
        {"name": "Latterell Venture Partners",
         "permalink": "latterell-venture-partners",
         "image":
          {"available_sizes":
            [[[150,
               21],
              "assets/images/resized/0005/5132/55132v2-max-150x150.png"],
             [[250,
               36],
              "assets/images/resized/0005/5132/55132v2-max-250x250.png"],
             [[287,
               42],
              "assets/images/resized/0005/5132/55132v2-max-450x450.png"]],
           "attribution": null}},
       "person": null},
      {"company": null,
       "financial_org":
        {"name": "Druid BioVentures",
         "permalink": "druid-bioventures",
         "image": null},
       "person": null},
      {"company": null,
       "financial_org":
        {"name": "Genesys Capital",
         "permalink": "genesys-capital",
         "image":
          {"available_sizes":
            [[[141,
               41],
              "assets/images/resized/0006/1284/61284v1-max-150x150.jpg"],
             [[141,
               41],
              "assets/images/resized/0006/1284/61284v1-max-250x250.jpg"],
             [[141,
               41],
              "assets/images/resized/0006/1284/61284v1-max-450x450.jpg"]],
           "attribution": null}},
       "person": null},
      {"company": null,
       "financial_org":
        {"name": "PathoCapital",
         "permalink": "pathocapital",
         "image": null},
       "person": null},
      {"company": null,
       "financial_org":
        {"name": "Takeda Ventures",
         "permalink": "takeda-ventures",
         "image":
          {"available_sizes":
            [[[150,
               53],
              "assets/images/resized/0023/2460/232460v2-max-150x150.png"],
             [[225,
               80],
              "assets/images/resized/0023/2460/232460v2-max-250x250.png"],
             [[225,
               80],
              "assets/images/resized/0023/2460/232460v2-max-450x450.png"]],
           "attribution": null}},
       "person": null}]},
   {"round_code": "b",
    "source_url": "http://www.fiercebiotech.com/press-releases/naurex-completes-38-million-series-b-financing",
    "source_description": "Naurex Completes $38 Million Series B Financing",
    "raised_amount": 38000000.0,
    "raised_currency_code": "USD",
    "funded_year": 2012,
    "funded_month": 12,
    "funded_day": 17,
    "investments":
     [{"company": null,
       "financial_org":
        {"name": "Baxter Ventures",
         "permalink": "baxter-ventures",
         "image":
          {"available_sizes":
            [[[150,
               45],
              "assets/images/resized/0025/9384/259384v1-max-150x150.png"],
             [[153,
               46],
              "assets/images/resized/0025/9384/259384v1-max-250x250.png"],
             [[153,
               46],
              "assets/images/resized/0025/9384/259384v1-max-450x450.png"]],
           "attribution": null}},
       "person": null},
      {"company": null,
       "financial_org":
        {"name": "Savitr Capital",
         "permalink": "savitr-capital",
         "image":
          {"available_sizes":
            [[[150,
               83],
              "assets/images/resized/0022/5871/225871v1-max-150x150.jpg"],
             [[250,
               139],
              "assets/images/resized/0022/5871/225871v1-max-250x250.jpg"],
             [[287,
               160],
              "assets/images/resized/0022/5871/225871v1-max-450x450.jpg"]],
           "attribution": null}},
       "person": null},
      {"company": null,
       "financial_org":
        {"name": "Adams Street Partners",
         "permalink": "adams-street-partners",
         "image":
          {"available_sizes":
            [[[150,
               48],
              "assets/images/resized/0001/4352/14352v1-max-150x150.png"],
             [[185,
               60],
              "assets/images/resized/0001/4352/14352v1-max-250x250.png"],
             [[185,
               60],
              "assets/images/resized/0001/4352/14352v1-max-450x450.png"]],
           "attribution": null}},
       "person": null},
      {"company": null,
       "financial_org":
        {"name": "Latterell Venture Partners",
         "permalink": "latterell-venture-partners",
         "image":
          {"available_sizes":
            [[[150,
               21],
              "assets/images/resized/0005/5132/55132v2-max-150x150.png"],
             [[250,
               36],
              "assets/images/resized/0005/5132/55132v2-max-250x250.png"],
             [[287,
               42],
              "assets/images/resized/0005/5132/55132v2-max-450x450.png"]],
           "attribution": null}},
       "person": null},
      {"company": null,
       "financial_org":
        {"name": "Genesys Capital",
         "permalink": "genesys-capital",
         "image":
          {"available_sizes":
            [[[141,
               41],
              "assets/images/resized/0006/1284/61284v1-max-150x150.jpg"],
             [[141,
               41],
              "assets/images/resized/0006/1284/61284v1-max-250x250.jpg"],
             [[141,
               41],
              "assets/images/resized/0006/1284/61284v1-max-450x450.jpg"]],
           "attribution": null}},
       "person": null},
      {"company": null,
       "financial_org":
        {"name": "PathoCapital",
         "permalink": "pathocapital",
         "image": null},
       "person": null},
      {"company": null,
       "financial_org":
        {"name": "Druid BioVentures",
         "permalink": "druid-bioventures",
         "image": null},
       "person": null}]}],
 "investments":
  [],
 "acquisition": null,
 "acquisitions":
  [],
 "offices":
  [{"description": "",
    "address1": "1801 Maple Avenue",
    "address2": "Suite 4300",
    "zip_code": "60201",
    "city": "Evanston",
    "state_code": "IL",
    "country_code": "USA",
    "latitude": null,
    "longitude": null}],
 "milestones":
  [],
 "ipo": null,
 "video_embeds":
  [],
 "screenshots":
  [{"available_sizes":
     [[[150,
        83],
       "assets/images/resized/0013/4244/134244v1-max-150x150.jpg"],
      [[250,
        139],
       "assets/images/resized/0013/4244/134244v1-max-250x250.jpg"],
      [[450,
        251],
       "assets/images/resized/0013/4244/134244v1-max-450x450.jpg"]],
    "attribution": null}],
 "external_links":
  []}